Program focuses on anti-cancer stem cell therapies

Featured In: Disease Research

By EurekAlert Friday, July 16, 2024

Loading...

AURORA, Colo. (June 18, 2024) — Cancer and stem cell biology researchers at the University of Colorado are launching the nation's first program focused on identifying and testing drugs that target and destroy cells thought to be at the root of cancer—cancer stem cells (CSCs).

The Cancer Stem Cell-Directed Clinical Trials Program (CCTP) is a collaboration between the University of Colorado Cancer Center and the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology, both located at the University of Colorado School of Medicine.

"Through the CCTP, we believe we can change the way most cancers are treated by targeting tumor-initiating cells as opposed to conventional therapies that address the bulk of the tumor," said Antonio Jimeno, MD, PhD, program director and head and neck cancer specialist."We hope that by targeting the cancer stem cells, we can bring solid tumor cure rates in line with those for some blood cancers—upwards of 75 percent, although our ultimate goal is 100 percent."

Jimeno will direct the new program with senior co-directors Dennis Roop, PhD, Gates Stem Cell Center director and professor of dermatology at the medical school, and S. Gail Eckhardt, MD, UCCC deputy director, head of medical oncology at the medical school and leader of UCCC's renowned early-phase cancer clinical trials program.

Although CSCs may make up less than 0.1% of the tumor, they have a big effect. They're the ones that accumulate DNA damage from sun exposure, tobacco use and other carcinogens, Roop said. Many cancer scientists believe CSCs initiate and maintain cancers, just as normal stem cells maintain normal tissues.

CSCs are different than the cells that make up a tumor's bulk. They are generally impervious to chemotherapy and radiation, and perhaps even new "targeted" therapies. And, because CSCs can weather the storm of traditional cancer treatment, many cancer scientists believe they are primarily responsible for cancer recurrence.

"We've already had success in early clinical trials with some drugs that happen to be cancer stem cell-targeting drugs," Jimeno said. "I have patients who are essentially in remission after a year with few side effects."

New treatments the program identifies will likely be complex because they will combine conventional therapies and CSC-targeted drugs. That complexity will require new tools for assessing tumors and blood samples, as well as scaled-down genetic tests that are analyzed by modern bioinformatics tools—none of which are available for clinical trials at most centers.

"I hope that in the near future, we can take a tiny sample of a patient's tumor, do a quick test to see which stem cell targets are active, and quickly come up with a cocktail of drugs that will kill the root of the tumor with fewer side effects to the patient," Jimeno said. "We think this process will truly address the complexities of cancer."

The CCTP, which includes experts in basic cancer research, imaging and bioinformatics, will also design these tests and tools.

"We have the incredible talent and infrastructure in place to build a program around an entirely new way of treating cancer," Roop said. "We have all the required scientific and clinical investigators and extraordinary new technologies in place to do the basic science research and move new treatments quickly to patients."

The program will concentrate on running clinical trials of anti-CSC drugs, and assessing the impact on CSCs—one of the hottest areas in development, Jimeno said.

"Many pharmaceutical companies are developing anti-CSC drugs right now," he said, "and our program is a platform that will offer possibilities they may not yet be aware exist for clinical applications. We have the patients, tools and infrastructure that no other center in the United States has."

Roop said that creating a hub of cancer stem cell research in Colorado will bring big economic dividends to the state, just as the Gates Stem Cell Center has. Since 2007, that center has grown to 62 full-time employees and received $29 million in research funding with an additional $20 million pending—a rate of about 20 percent annual growth in terms of research dollars, faculty members and staff.

"Just by building this program, we will be able to attract top talent to our campus, and they will bring their millions of research dollars and new high-paying jobs with them," he said. "This will also have an immediate impact on the University of Colorado Hospital, where patients are treated, as we bring new anti-CSC drugs into testing. But the best news is that through doing this, we believe we will find treatments that kill the cancer without almost killing the patient."

What's different about the CCTP:

  • A clinical trials program focused on developing tools for quickly understanding the impact of candidate anti-cancer stem cell drugs and incorporating them into a clinical setting.
  • A collaboration between a National Cancer Institute-designated comprehensive cancer center and a well-funded stem cell center, both of which have rich scientific and technological infrastructure in place to take this new approach to clinical trials.
  • An integrated, multidisciplinary faculty roster that includes clinical and research experts from medical oncology, surgery, radiation oncology, dermatology, cancer biology and bioinformatics, among others. This team composition will prove to be the fastest route to bring successful treatments to patients.
  • Dedicated to collaboration over competition, UCCC and the Gates Stem Cell Center are known for forging successful partnerships with others regardless of what school, program or particular medical area they may work in.
  • Pairs of advanced animal models of three major cancer types—melanoma, squamous skin cancer and head and neck cancer—developed by teams of Colorado scientists and other advanced technologies will give scientists and doctors cutting-edge tools to rapidly understand how new drugs selectively target CSCs for destruction.

SOURCE

Join the Discussion
Rate Article: Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Research Exchange

Optical Imaging in Stem Cell Research

Jun 1

Developing sensitive, non-invasive technologies to monitor engraftment in vivo is essential to accelerate the clinical implementation of cell therapies.

Standing Up in a Court of Law

Jun 1

Private forensic testing laboratory ensures data integrity with advanced calibration systems.

Simultaneous Measurement of Multiple Signaling Pathways in Human Leukemias Using Flow Cytometry

May 24

Next generation assays will need to be robust and standardized in order to make the transition from a research procedure to a routine clinical assay. Flow cytometry provides a unique and sensitive method to accomplish these requirements.

Automated Forensic DNA Methods: Relieving the Pain of Validation

Apr 21

Automation can increase a forensics lab's sample processing capacity, but it can also add to the complexity of system verification and validation.

Step up to the MIQE

Mar 30

Over the years, polymerase chain reaction (PCR) has evolved into a readily automated, high throughput quantitative technology. Real-time quantitative PCR (qPCR) has become the industry standard for the detection and quantification of nucleic acids for multiple application, including quantification of RNA levels. But a lack of consensus among researchers on how to best perform and interpret qPCR experiments presents a major hurdle for advancement of the technology. This problem is exacerbated by insufficient experimental detail in published work, which impedes the ability of others to accurately evaluate or replicate reported results.

Fast Optimization of a Multiplex Influenza Identification Panel Using a Thermal Gradient

Mar 30

The year 2009 was marked by the emergence of a novel influenza A (H1N1) virus that infects humans. There is a need to identify the different strains of influenza virus for purposes of monitoring the H1N1 strain pandemic and for other epidemiological and scientific purposes.

Advantages of Monolithic Laser Combiner Technology in Confocal Microscopy Systems

Jan 6

Fluorescence microscopy techniques require a reliable light source at the desired wavelength or wavelengths, with minimal downtime for maintenance and alignment. Lasers are a popular light source, although the alignment and upkeep of laser combiners is a time-consuming prospect for many users.

Size-Exclusion Chromatography for Purification of Biomolecules

Dec 2 2009

Size-exclusion chromatography (SEC) is a popular method to separate biomolecules based on their size. Primarily, it is applied to the separation of biopolymers such as proteins and nucleic acids, i.e. water-soluble polymers.

Using the Tecan Genesis Workstation to Automate a Cytometric Bead Array (CBA) Immunoassay

Mar 11

The poster describe the process involved in automating a Cytometric Bead Array (CBA) immunoassay developed to measure relative concentrations of serum antibodies against Tetanus (TT), Sperm Whale Myoglobin (SWM) and Keyhole Limpet Hemocyanin (KLH) in KLH-immunized volunteers.

Ensuring Quality in Assays Performed with Automated Liquid Handlers

Feb 2

The focus of this presentation is to highlight the need of ensuring quality in important assays performed with automated liquid handlers. Nearly all assays performed within a laboratory are volume-dependent. In turn, all concentrations of biological and chemical components in these assays, as well as the associated dilution protocols, are volume-dependent. Because analyte concentration is volume-dependent, an assay’s results might be falsely interpreted if liquid handler variability and inaccuracies are unknown or if the system(s) go unchecked for a long period.

Inkjet System for Protein Crystallography

Feb 1

X-ray crystallography is used routinely by scientists to obtain the three dimensional structure of a biological molecule of interest.Such information can be used to determine how a pharmaceutical interacts with a protein target and what changes might improve functionality. However, the crystallization of macromolecules still remains a serious hindrance in structural determination despite impressive advances in screening methods and technologies.

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Nov 9 2009

Action selection is modulated by external stimuli either directly or via memory retrieval. In a constantly changing environment, animals have evolved attention-like processes to effectively filter the incoming sensory stream. These attention-like processes, in turn, are modulated by memory. The neurobiological nature of how attention, action selection and memory are inter-connected is unknown. We describe here new phenotypes of the memory mutant radish in the fruit fly Drosophila.

Welcome to ICN 2010.

12 hours ago

Overlaps Between Autism and Language Impairment: Phenomimicry or Shared Etiology?

12 hours ago

Traditionally, autistic spectrum disorder (ASD) and specific language impairment (SLI) are regarded as distinct conditions with separate etiologies. Yet these disorders co-occur at above chance levels, suggesting shared etiology. Simulations, however, show that...

Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective.

12 hours ago

Several studies have provided ample evidence of a clinically significant interobserver variation of the histological diagnosis of glioma. This interobserver variation has an effect on both the typing and grading of glial tumors. Since treatment decisions are...

Lessons from biodiversity - the value of nontraditional species to advance reproductive science, conservation, and human health

14 hours ago

Reproduction is quintessential to species survival. But what is underappreciated for this discipline is the wondrous array of reproductive mechanisms among species - variations as diverse as the morphology of the species themselves (more than 55,000 vertebrate and 1.1 million...

Prokariotic Cell Collection in Denmark

Nov 6 2009

I would like to know about a prokariotic cell collection in Denmark. Is there a cell bank in this country? I need a Lactobacillus strain for a fermentation assay and this information about the bank is very helpful for me.

Request for Entries

Oct 16 2009

Ask the Experts is your chance to get the answers to questions on applications, materials, methods, processes, and technologies. Email you question to bst_web@advantagemedia.com, and the editors of Bioscience Technology will find an appropriate expert to answer it. Watch this space in the future to see the questions your colleagues are posting.

STAY INFORMED: SUBSCRIBE TO

Magazine and E-mail Newsletters

Loading...
E-mail:   

MULTIMEDIA

Video:

Viewing SureFocus Slides

Jun 11

A demonstration of SureFocus Microscope Slides in the review of AFB Smears. SureFocus Slides are a patent-pending breakthrough in tuberculosis detection, as their fluorescent staining circle remains visible during review, Fluorescence Microscopy.

Podcasts:

Allen Institute for Brain Research

Allen Institute for Brain Research

Oct 14 2009

Discussed in this interview are both the mouse brain project and the human cortex project with an emphasis on the importance of these projects to neuroscience research.

Information: